Abstract
BackgroundLarge scale randomized studies are underway to assess whether compared to placebo, each XO-inhibitor, allopurinol or febuxostat, can prevent renal function loss. This evidence is needed and will confirm their...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
